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The production of equilin and the other ring B-unsaturated estrogens by the pregnant mare is anomalous 
in that they are biosynthesised by a cholesterol-independent pathway. Fetal horse gonads were incubated 
with tritiated sodium acetate and radiochemically pure 3,&hydroxy-5,7-pregnadien-20-one and 3& 
hydroxy-5,7-androstadien-17-one were isolated. A fetal gonad-placental system is proposed for equilin 
production, 3&hydroxy-5,7-pregnadien-20-one b ing a precursor for 3&hydroxy-5,7-androstadien-17-one 
in the fetal gonad and the latter being the precursor of equilin in the placenta. The nature of the possible 
precursor of 3fl-hydroxy-5,7-pregnadien-20-one is discussed. 
Equilin Biosynthesis Precursor Horse Fetal gonad 
1. INTRODUCTION 
The blood and urine of pregnant mares have 
high concentrations of estrogens; e.g., estrone (I) 
and also ring B unsaturated estrogens; e.g., equilin 
(II). It has been shown that whereas estrone is 
formed by the classical triterpene (C 30) pathway 
of steroid biosynthesis equilin is biosynthesised by 
an alternative route which avoids both squalene 
and cholesterol [1,2]. It has been proposed that 
this alternative route could be a sesterterpene (C 
25) pathway [3,4]. 
17-one which is biosynthesised in the fetal gonad. 
This proposal is analogous to the fetal adrenal- 
placental system for estrogen biosynthesis in 
human pregnancy [lo]. 
The possibility has now been examined that 
other 5,7-dienes could be produced by the horse 
fetal gonad and this report describes the biosyn- 
thesis of 3,&hydroxy-5,7-pregnadien-20-one (IV). 
2. EXPERIMENTAL 
A prerequisite for the formation of ring B un- 
saturated estrogens by human and horse placenta 
in vitro is the presence of a 7(8) double bond in the 
C 19 precursor [5,6,7]. The horse fetal gonad is im- 
plicated in the provision of substrates for subse- 
quent estrogen formation in the placenta [8,9] and 
it has recently been shown that the gonadal tissue 
can biosynthesize 3/3-hydroxy-5,7_androstadien- 
17-one (III) from radioactive acetate in vitro [4]. 
From these findings it was proposed that, in the 
pregnant mare, equilin is produced in the placenta 
by aromatisation of 3fl-hydroxy-5,7-androstadien- 
3,&-Hydroxy-5,7-pregnadien-20-one and 3fl- 
hydroxy-5,7-androstadien-17-one w re synthesised 
as in [l 11. Thin-layer chromatography (TLC) was 
carried out on 0.25 mm thick layers of Kieselgel 
HF 254/366 (Merck). The solvent systems used 
were: cyclohexane-acetone ((A) 3 :2, v/v; (B) 
19: 1, v/v); cyclohexane-ethyl acetate ((C) 2 : 1, 
v/v; (D) 9: 1, v/v); toluene-diethyl ether ((E) 2: 1, 
v/v; (F) 3 : 1, v/v); toluene-ethyl acetate ((G) 2: 1, 
v/v); petroleum ether (b.p. 60-80”C)-ethyl acetate 
((H) 9: 1, v/v); dichloromethane-acetone ((I) 
49 : 1, v/v). High pressure liquid chromatography 
(HPLC) was carried out on a Waters radial com- 
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pression C-18, 10pM column using 10% water in 
methyl alcohol as the mobile phase. Procedures for 
reduction, acetylation and hydrolysis of steroids 
were as described in [ 121. 
2.1. Experiment 1 
Fetal gonad (2.7 g from an g-month fetus) was 
finely chopped, suspended in Eagles medium 
(10 ml) containing sodium [3H]acetate (37 MBq, 
spec. act. 11.1 MBq/mmol) and 3/Y-hydroxy-5,7- 
pregnadien-20-one (0.16 pmol) and incubated at 
37°C for 3 h in an atmosphere of oxygen/carbon 
dioxide (95: 5). Ethyl alcohol (10 ml) was added 
and the mixture extracted with diethyl ether (3 x 
50 ml). The organic phases were combined, wash- 
ed with water and the solvent evaporated leaving a 
residue which was separated into a sterol and 
steroid fraction by TLC in system A. 
The steroid fraction was acetylated, 
chromatographed in system E and then on a silver 
nitrate/silica gel plate [4] in solvent C which sepa- 
rated 3/3-hydroxy-5,7-pregnadien-20-one acetate, 
3,0-hydroxy-5,7-androstadien-17-one acetate and 
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pregnenolone-dehydroepiandrosterone (DHA) 
acetates. 3,&Hydroxy-5,7-pregnadien-20-one 
acetate was further purified by TLC in system 
F, then by HPLC, diluted with carrier steroid 
(70 pmol) and crystallized to constant specific 
radioactivity. Radiochemical purity was confirmed 
by further recrystallizations after converting to 
derivatives (table 1). 3,&Hydroxy-5,7-androsta- 
dien- 17-one was purified similarly and crystallized 
(table 1). 
Pregnenolone and DHA acetates were separated 
in system F, and both chromatographed in systems 
I and G, carrier steroid (150 pmol) added and 
crystallized to constant spec. act. (table 1). 
2.2. Experiment 2 
Fetal gonadal tissue (2.5 g) was homogenised 
and incubated in 0.1 mM phosphate buffer (pH 
7.4, 10 ml) containing nicotinamide (30 mM), 
magnesium chloride (4 mM), reduced glutathione 
(8 mM), glucose-6-phosphate (6 mM) and NADP 
(0.1 mM) [3]. The substrates were [4-r4C]cho- 
lesterol (185 kBq, spec. act. 1.85 GBq/mmol) 
and 23,24-dinor-[7a-3H]-5-cholen-3P-ol (VI) 
(1.48 MBq, spec. act. 48 GBq/mmol) [3] and the 
incubation was carried out at 37°C for 2 h in air. 
The incubation was extracted and DHA isolated 
and crystallized as above (table 2). 
3. RESULTS AND DISCUSSION 
The isolation and rigorous purification of 3,0- 
hydroxy-5,7-pregnadien-20-one (IV) by formation 
of derivatives and recrystallization demonstrates 
that the fetal horse gonad can biosynthesize this 
21-carbon (C 21) 5,7-diene from radioactive 
acetate in vitro (incorporation 0.001%) (table 1). 
The 19-carbon (C 19) 5,7-diene, 3,&hydroxy-5,7- 
androstadien-17-one (III) was also produced (in- 
corporation 0.005~0) (table 1) confirming our 
previous finding [4]. 
Pregnenolone and DHA were also isolated from 
this incubation (table 1). In the classical biosyn- 
thetic pathway pregnenolone (C 21) is a precursor 
of DHA (C 19) and it is considered possible, by 
analogy, that 3,&-hydroxy-5,7-pregnadien-20-one 
(C 21) is a precursor of 3fl-hydroxy-5,7-androsta- 
dien-17-one (C 19). It is therefore suggested that, 
in this tissue, there is a 5,7-diene pathway 
operating in parallel to the classical pathway. 
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Table 1 
Radiochemical purity of steroids isolated from expt 1 
Steroid Derivative formed Spec. act.a 
dpm/pmol (SD) 
3fl-Hydroxy-5,7-pregnadien-20-one - 
3,&Hydroxy-5,7-pregnadien-20-one acetate 
5,7-Pregnadiene-3/?,2O&diol 3-acetate 
5,7-Pregnadiene-3@,2OP_diol diacetate 
3.43 x 10’ (0.02) 
3.45 x IO5 (0.04) 
3.46 x lo5 (0.08) 
3.56 x lo5 (0.04) 
3&Hydroxy-5,7-androstadien-17-one _ 
3&Hydroxy-5,7-androstadien-17-one acetate 
5,7-Androstadiene_3fl, 17,&diol 3-acetate 
Pregnenolone 
(3/3-Hydroxy-5-pregnen-20-one) - 
3&Hydroxy-5-pregnen-20-one acetate 
S-Pregnene-3P,20@-diol 3-acetate 
Dehydroepiandrosterone 
(3,&Hydroxy-S-androsten-17-one) - 
3&Hydroxy-5-androsten-17-one acetate 
S-Androstene-3,&,17P-diol diacetate 
_ 
6.95 x lo5 (0.15) 
7.41 x 10’ (0.06) 
- 
1.51 x lo4 (0.07) 
1.50 x lo4 (0.08) 
- 
1.43 x lo5 (0.07) 
1.32 x 10’ (0.04) 
a The spec. act. were judged to be constant when 3 crops agreed to within + 5%. For brevity only the means and 
standard deviations of the spec. act. of each derivative are shown 
Table 2 
Radiochemical purity of dehydroepiandrosterone isolated from expt 2 
Steroid Derivative formed Spec. act. dpm/hmol (SD) 3H/14C 
Tritium Carbon-l4 
Dehydroepiandro- 3&Hydroxy-5-androsten-17-one acetate 3.37 x lo4 (0.20) 9.77 x lo4 (0.16) 0.35 
sterone 5-Androstene-3fl,17&diol 3-acetate 3.65 x lo4 (0.06) 9.54 x lo4 (0.04) 0.38 
(3,&Hydroxy-5- S-Androstene-3,&,17&diol diacetate 3.89 x lo4 (0.04) 9.88 x lo4 (0.12) 0.39 
androsten-17-one) 
C x-5,7-diene- 
C 21-5,7-diene- C 19-5,7-diene 
3&hydroxy- 3&hydroxy- 
5,7-pregnadien- 5,7-androstadien- 
20-one 17-one 
It has been suggested that this 5,7-diene pathway 
could be a sesterterpene pathway [3,4], with 
23,24-dinor-5,7-choladien-3P_ol (V), analogous to 
7-dehydrocholesterol n the classical pathway, be- 
ing the appropriate intermediate. 23,24-Dinor-5- 
cholen-3,&ol (VI) is also a possible intermediate on 
the sesterterpene pathway and it has been shown to 
be converted to steroid hormones by canine and 
bovine adrenals [3,13] and by two human corticos- 
terone secreting adrenal adenomata [14]. DHA 
containing both 3H and 14C was isolated when 
tritiated 23,24-dinor-5-cholen-3P_ol and 14C-label- 
led cholesterol were incubated with this tissue 
(table 2). The presence of 14C in the DHA confirm- 
ed the previous finding that cholesterol is con- 
verted to DHA [4] and the 3H shows that the horse 
163 
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fetal gonad can convert the 5-ene, 23,24-dinor-5- 
cholen-3,&ol (VI) to DHA. That is, this tissue can 
utilise a material with the 23,24_dinorcholane car- 
bocyclic system to produce steroids which are 
usually thought to be derived from cholesterol. It 
is hoped to test whether the 5,7-diene, 23,24-dinor- 
5,7-choladien-3,&-ol (V) will yield 3&hydroxy-5,7- 
androstadien-17-one (III) with the material 
reported in this paper 3,8-hydroxy-5,7-pregnadien- 
20-one (IV) as an intermediate. 
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